British Journal of Cancer

EDITORIAL BOARD

Editor
P.R. Twentyman
Cambridge

Chairman
D.G. Harnden
Manchester

Clinical Editor
P.J. Selby
Leeds

G.E. Adams – Didcot, Oxon
P. Alexander – Southampton
K.D. Bagshawe – London
M. Baum – London
C.C. Bird – Edinburgh
D.T. Bishop – Leeds
N.M. Bleehen – Cambridge
P. Boyle – Lyon
D.N. Carney – Dublin
C.E.D. Chilvers – Nottingham
F.J. Cleaton – Leiden
T.A. Connors – Sutton
D. Crowther – Manchester
G.A. Currie – Oxted, Surrey
J. Denekamp – Northwood
M. D’Incalci – Milan
M.J. Embleton – Nottingham
P. Gallimore – Birmingham
C.F. Graham – Oxford
J.D. Hardcastle – Nottingham
K.R. Harrap – Sutton
A.L. Harris – Oxford
D. Heath – Birmingham
J. Hickman – Manchester
A. Horwich – Sutton
D.K. Hossfeld – Hamburg
A. Howell – Manchester

Editorial Assistants
Janice Baiton – Cambridge

B. Ketterer – London
L.J. Kinlen – Edinburgh
R.C.F. Leonard – Edinburgh
J.O’D. McGee – Oxford
J.G. McVie – London
J. Malpas – London
C. Marshall – London
D. Metcalf – Melbourne
N.A. Mitchison – London
M. Moore – Slough
T.J. Perren – Leeds
B. Ponder – Cambridge
J. Pritchard – London
T.J. Priestman – Birmingham
R.L. Souhami – London
I.F. Tannock – Toronto
G.M. Taylor – Manchester
J.M. Trent – Ann Arbor
V. Van Heyningen – Edinburgh
M.P. Vessey – Oxford
N.J. Wald – London
P. Wardman – Northwood
R.A. Weiss – London
N.M. Wilkie – Glasgow
R.C.N. Williamson – London
P. Workman – Glasgow
J.A. Wyke – Glasgow

Diane Roberts – Leeds
for the treatment of tumour-induced hypercalcaemia

- **Reliable response**
  “Calcium concentration fell in all patients [n=30]
  and was restored to normal in all but two”\(^1\)

- **Sustained effectiveness**
  Normocalcaemia maintained for an average of 3 weeks\(^1\)

- **Well tolerated**
  Reported side-effects not of clinical relevance\(^{1,2}\)

- **Effective as a single infusion**

**Presentation** Ampoules of 5ml aqueous injectable concentrate containing 15mg pamidronate disodium (calculated as the anhydrous form) for intravenous infusion.

**Indication** Tumour-induced hypercalcaemia.

**Dosage** Adults and elderly: Depending on the initial calcium plasma level, 15-90mg by slow intravenous infusion in sodium chloride 0.9% or dextrose 5%. Infusion rate should not exceed 15mg/2 hours, and concentration should not exceed 90mg/l. Total dose can be given as a single i.v. infusion or divided over 2-4 consecutive days. Not recommended for children. Rehydration with normal saline before treatment is recommended.

**Contraindications** Known hypersensitivity to pamidronate disodium.

**Precautions** Do not administer as a bolus injection. Do not co-administer with other bisphosphonates, plicamycin (mithramycin) or calcium-containing i.v. infusions. Beware of slight transient hypocalcaemia when the dose given is too high in relation to initial plasma calcium levels. Caution in patients with severe renal insufficiency (multiple dosing recommended); convulsions; oliguria; pregnancy; interference with bone scintigraphy examinations.

**Side-effects** Mild, transient 1-2°C temperature rise at onset of treatment, transient decreased lymphocyte count; neither appears to be clinically significant.

**Packs** Ampoules 15mg/5ml (PL0001/0138) in packs of 4, basic NHS price £96.62. \(^{a}\) denotes registered trademark. Full prescribing information is available on request from Ciba Laboratories, Horsham, West Sussex.

Immunohistochemical characterisation of extracellular matrix components of salivary gland tumours
The prognostic value of the monoclonal antibody (D5) detected protein, p29, in primary colorectal carcinoma
Robertson, J.F.R., Morris, D.L., Ellis, I.O., Armitage, N.C., Hardcastle, J.D.

Sarcomas in North West England: A histopathological peer review

No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited

Flow cytometric DNA ploidy pattern in dysplastic mucosa, and in primary and metastatic carcinomas in patients with longstanding ulcerative colitis
Meling, G.L., Clausen, O.P.F., Bergan, A., Schjelberg, Aa., Rognum, T.O.

Antibody BNH9 detects red blood cell-related antigens on anaplastic large cell (CD30 + ) lymphomas

Assessment of qualify of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party
MRC Lung Cancer Working Party, Fayers, P.M., Bleehen, N.M., Girling, D.J., Stephens, R.J.

Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis
Thompson, S., Cantwell, B.M.J., Cornell, C., Turner, G.A.

Rapid VAC, high dose melphalan regimen. A novel chemotherapy approach in childhood soft tissue sarcomas

Oncologists vary in their willingness to undertake anti-cancer therapies
Lind, S.E., Del Vecchio Good, M.-J., Schafer, C., Good, B.J.

Studies on cyclosporin-A for reversal of multidrug resistance in colorectal cancer

---

Editorial Announcement

This issue of the British Journal of Cancer contains a revised version of the ‘Notice to Contributors’.

The changes from the previous version are mainly clarifications of existing instructions. The format for ‘Short Communications’ has however been substantially revised. We now ask that such papers contain the usual section headings plus a short summary of around 50 words. This will make it possible for summaries to be included in computer databases.

There are two changes in the format for references. We now require that the names of all authors are given in the reference list, even when there are more than 6 authors. In addition, the first and last page numbers of all referenced papers and book chapters are to be given.

In accordance with the practise of almost all other biomedical journals we now find it necessary to charge authors for all colour illustrations and this is now pointed out in the ‘Notice to Contributors’.
120 Fludarabine phosphate for the treatment of low grade lymphoid malignancy

124 The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer

128 Defective erythropoiesis in primary myelofibrosis associated with a chromosome 11 abnormality
Patton, W.N., Bunce, C.M., Larkins, S. & Brown, G.

132 Laterality, maldescent, trauma and other clinical factors in the epidemiology of testis cancer in Victoria, Australia
Stone, J.M., Cruickshank, D.G., Sandeman, T.F. & Matthews, J.P.

139 DNA ploidy of primary breast cancer and local recurrence after breast-conserving therapy

144 The antileukaemic activity of 5-Aza-2-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia
Richel, D.J., Colly, L.P., Kluiin-Nelemans, J.C. & Willemze, R.

149 Seasonal changes in serum melatonin in women with previous breast cancer

154 Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up breast cancer patients
Nicollini, A., Colombini, C., Luciani, L., Carpi, A. & Giuliani, L.

159 Cancer risks in thyroid cancer patients

164 Raised levels of latent collagenase activating angiogenesis factor (ESAF) are present in actively growing human intracranial tumours
Taylor, C.M., Weiss, J.B. & Lye, R.H.

169 The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia

174 c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis

179 Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas

182 Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor
Scambia, G., Benedetti, P., Ferrandina, G., Battaglia, F., Baiocchi, G. & Mancuso, S.

185 Cancer patterns among Vietnamese immigrants in Los Angeles County
Ross, R.K., Bernstein, L., Harinett, N.M. & Boone, J.R.

187 The role of diet in the development of breast cancer: a case-control study of patients with breast cancer, benign epithelial hyperplasia and fibrocystic disease of the breast
Ingram, D.M., Nottage, E. & Roberts, T.

Review
192 Drug-target interactions: only the first step in the commitment to a programmed cell death?
Dove, C. & Hickman, J.A.

Meeting Report
197 25th Paterson Symposium – Is there a Future for Radiosensitivity Testing?

Correspondence
200 Lung cancer and passive smoking (continued)
Lee, P.

201 Response to letter from Dr Lee
Ward, N., Cuckle, H., Nanchahal, K. & Thompson, S.

202 Erratum

SECOND INTERNATIONAL CONGRESS ON ORAL CANCER

2–5 December 1991
New Delhi, India

Organising Secretary: Mrs. Arati Walia
2nd ICOOC
B-4, South Extension, Part-II
New Delhi - 110049, India
Tel: 6462354 Telex: 031 66956 AKASIN
Fax: 91-11-6444966
Aims and Scope

The British Journal of Cancer will accept papers which contain new information, constitute a distinct contribution to knowledge, and are relevant to the clinical, epidemiological, pathological or molecular aspects of oncology.

The Journal is published monthly on behalf of the Cancer Research Campaign by the Scientific and Medical Division of Macmillan Press Ltd.

Copyright © 1991 Cancer Research Campaign. ISSN 0007-0920.

Manuscripts plus two copies and all editorial correspondence should be sent to: Dr P.R. Twentyman, Editor, British Journal of Cancer, MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK.
Telephone: (0223) 210115
Fax: (0223) 213556

All business correspondence and reprint requests should be addressed to the Scientific & Medical Division, Macmillan Press Ltd., Houndmills, Basingstoke, Hampshire RG21 2XS, UK.
Telephone: (0256) 29242
Fax: (0256) 810526

Annual subscription prices: EEC £280, elsewhere £310/US $620 (sterling rate is definitive). Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Press and sent to: Subscription Department, Macmillan Press, Brunel Road, Houndmills, Basingstoke, RG21 2XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Second class postage permit USPS 689–430.

Postmaster please send address corrections to Mercury Airfreight International Ltd., 2323 E-F Randolph Avenue, Avenel, NJ 07001, USA (US Mailing agent). Second class postage paid at Rahway, NJ.

Enquiries concerning advertising space or rates should be addressed to: Michael Rowley, Advertisement Manager, Macmillan Press Ltd., 4 Little Essex Street, London.
Telephone: 071 836 6633, Fax: 071 379 4204.

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Macmillan Press Ltd for libraries and other users registered with the Copyright Clearance Centre (CCC) Transactional Reporting Service, provided that the base fee of $3.50 per copy, is paid directly to CCC, 27 Congress St., Salem, MA 01970, USA. 0007–0920/91 $3.50 + $0.00

Cover Illustration. A somatostatin analogue (SMS 201-995) is useful in the treatment of patients with midgut carcinoid syndrome. Tumour cells from patients with this syndrome are labelled by serotonin antibodies and by tachykinin antiserum (left hand panels – a and b respectively). Tumour cell cultures treated with SMS 201-995 show significantly lower levels than control of serotonin and of neuropeptide K-like immunoreactivity (right hand panels) (see paper by Wångberg et al., this issue p 23).

Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and The Fellowship, the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.

Typset by Elite Typesetting Techniques, Southampton
Printed in Great Britain by Unwin Brothers Ltd, The Gresham Press, Old Woking, Surrey
Editorials
Can we prevent breast cancer?
Baum, M., Ziv, Y., Colletta, A.

Genetic predisposition to cancer
Ponder, B. A. J.

Guest Editorial
Membrane-transcytotic vesicles as experimental anticancer drugs
Berdel, W. E.

Experimental Oncology
Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice
Kue, A., Sano, T., Naito, A., Okumura, M., Kohno, K., Kuwano, M.

Tumorogenic multidrug-resistant HT1080 cells do not overexose receptors for epidermal growth factor receptor
Slovak, M. L., Mirkov, S. E. L., Cole, S. P. C., Gerlach, J. H., Yohem, K. H., Trent, J. M.

Differences in EGF related radioresistinisation of human squamous carcinoma cells with high and low numbers of EGF receptors
Kwok, T. T., Sutherland, R. M.

An evaluation of ovarian carcinoma-associated antigen defined by murine monoclonal antibody CF511 in sera from patients with ovarian carcinoma
Ohkawa, K., Takada, K., Hatano, T., Takizawa, N., Takuda, Y., Yamada, K., Terashima, Y., Matsuda, M., Machida, K.

Characteristics and performance of a bispecific Fab(αγ) antibody for delivering the toxin saporin to a CD7+ human acute T-cell leukaemia cell line
Flavall, D. J., Cooper, S., Morland, B., Flavall, S. U.

Perforin expression in lymphocytes infiltrated to human colorectal cancer
Nakanishi, H., Monden, T., Morimoto, H., Kobayashi, T., Shimano, T., Mori, T.

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines
Mistry, P., Kelland, L. R., Abel, G., Sidbar, S., Harrap, K. R.

4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis

Selective immunotherapy of small cell cancer xenografts using 125I labelled SWA11 antibody
Smith, A., Waibel, R., Stahle, R. A.

Cisdichlorodiammineplatinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer
Balconi, G., Pang, Y., Broggiini, M., Morali, F., Marzola, M., Erba, E., Ponti, M., Spinelli, L., Mangioni, C., Redaelli, L., Bertolero, F., D’Incalci, M.

Effects of cyclosporin A on growth and polyamine metabolism of MOLT-4 T-lymphoblastic leukaemia cells
Mclachlin, G., Thomson, A. W., Wallace, H. M.

The uptake and retention of metiodobenzyl guanidine by the neuroblastoma cell line NBI-G
Moirs, R. J., Gaze, M. N., Barrett, A.

The paradoxical effects of somatostatin on the bioactivity and production of cytotoxins derived from human peripheral blood mononuclear cells
Yousefi, S., Vaziri, N., Carandang, G., Le, W., Yamamoto, R., Granger, G., Ocariz, J., Crespo, T.

Expression of P-glycoprotein restricted to normal cells in neuroblastoma biopsies

Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug conjugate
Sivolapenko, G. B., Moreno, C., Smith, W., Cors Ian, J., Ritter, M. A., Epenetos, A. A.

The effects of vasopression infusion on heptic haemodynamics in an experimental model of liver metastases
Hemmingway, D. M., Chang, D., Cooke, T. G., Jenkins, S. A.

Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype

Viral involvement in Hodgkin’s disease: detection of clonal type A Epstein-Barr virus genomes in tumour samples

Clinical Oncology/Epidemiology
Argyrophilic nuclear organiser region counts and prognosis in pharyngeal carcinoma
Pich, A., Pisani, P., Krengli, M., Cappello, N., Navone, R.

The roles of age and sex in the prognosis of chronic leukemias. A study of 373 cases
Jaksic, B., Vitale, B., Hauptmann, E., Peraica, A. P., Ostoijic, S., Kucec, R.

Prognostic value of serum thymin kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer

Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance

A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer
Powles, T. J., Jones, A. L., Judson, I. R., Hardy, J. R., Ashley, S. E.

Inter-clinician agreement on the recognition of clinical pigmented characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI
Roush, G. C., Barnhill, R. L., Ernstoff, M. S., Kirkwood, J. M.

Further evidence of an excess of risk of pleural malignant mesothelioma in textile workers in Prato (Italy)
Paci, E., Zappa, M., Poletti, L., Buatti, E., Cellini, E., Merler, E., Costantini, A. S.

Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-reporting questionnaires
Hopwood, P., Howell, A., Maguire, P.

Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires
Hopwood, P., Howell, A., Maguire, P.

Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours
Sanderson, V., Reeve, J. G., Stening, S., Stewart, S., Bleezen, N. M.

Glomerular filtration rate, 125I-hippuran clearance and estimated creatinine clearance in cancer patients
Lindegard, M. W., Aass, N., Bue, E. S., Theodorsen, L., Foss, S. D.

Regional chemotherapy for inoperable renal carcinoma: a method of targeting therapeutic microspheres to tumour

Palliation and life quality in lung cancer; how good are clinicians at judging treatment outcome?
Regan, J., Yarnold, J., Jones, P. W., Cooke, N. T.
Immunohistochemical characterisation of extracellular matrix components of salivary gland tumours
The prognostic value of the monoclonal antibody (D5) detected protein, p29, in primary colorectal carcinoma
Robertson, J.F.R., Morris, D.L., Ellis, I.O., Armitage, N.C., Hardcastle, J.D.
Sarcomas in North West England: I histopathological peer review
No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited
Flow cytometric DNA ploidy pattern in dysplastic mucosa, and in primary and metastatic carcinomas in patients with longstanding ulcerative colitis
Meling, G.I., Clausen, O.P.F., Bergan, A., Schjølberg, Aa., Rognum, T.O.
Antibody BNH9 detects red blood cell-related antigens on anaplastic large cell (CD30+) lymphomas

Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party
MRC Lung Cancer Working Party, Fayers, P.M., Bleehen, N.M., Girling, D.J., Stephens, R.J.
Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis
Thompson, S., Cantwell, B.M.J., Cornell, C., Turner, G.A.
Rapid VAC, high dose melphalan regimen. A novel chemotherapy approach in childhood soft tissue sarcomas
Oncologists vary in their willingness to undertake anti-cancer therapies
Lind, S.E., Del Vecchio Good, M.-J., Schaffer, C., Good, B.J.
Studies on cyclosporin-A for reversal of multidrug resistance in colorectal cancer

Editorial Announcement

This issue of the British Journal of Cancer contains a revised version of the ‘Notice to Contributors’.

The changes from the previous version are mainly clarifications of existing instructions. The format for ‘Short Communications’ has however been substantially revised. We now ask that such papers contain the usual section headings plus a short summary of around 50 words. This will make it possible for summaries to be included in computer databases.

There are two changes in the format for references. We now require that the names of all authors are given in the reference list, even when there are more than 6 authors. In addition, the first and last page numbers of all referenced papers and book chapters are to be given.

In accordance with the practise of almost all other biomedical journals we now find it necessary to charge authors for all colour illustrations and this is now pointed out in the ‘Notice to Contributors’. 
The criteria for acceptance of manuscripts to be published in the British Journal of Cancer are originality and high scientific quality. Manuscripts are accepted on the understanding that they report unpublished work that is not under consideration for publication elsewhere, that all named authors have agreed to its submission and that if accepted it will not be published in the same form, in any language, without the consent of the Publishers. Papers should be in English. Authors whose mother-tongue is not English are urgently requested to have their manuscripts checked for linguistic correctness before submission. The Editors reserve the right to make literary corrections.

Papers reporting clinical studies should, where appropriate, contain a statement that they have been carried out with ethical committee approval. Single case studies are not usually acceptable. Papers disregarding the welfare of experimental animals will be rejected. Authors may find the UKCC-CCR ‘Guidelines for the Welfare of Animals in Experimental Neoplasia’ helpful in this regard. These were published in the British Journal of Cancer (1988) 58, pp. 109–113. Alternatively, copies may be obtained from: UKCCCCR, P.O. Box 123, Lincoln’s Inn Fields, London WC2A 3PX, UK.

Manuscripts should be sent in triplicate (original plus two copies) to the Editor, Dr Peter Twyman. They should be typewritten, double-spaced with a wide margin and on one side of the paper only. They should be accompanied by a title page numbered as 1, bearing title, authors’ full names, affiliation and complete addresses, including postal (zip) codes; and a summary of not more than 200 words. The author and address to whom correspondence, proofs and reprint requests are to be sent should be clearly indicated. A series of Editorials explaining the editorial policies and practices of the British Journal of Cancer was published in the Journal between November 1990 and March 1991. Composite reprints of these articles are available from the Editor on request.

Full papers should be divided into sections:
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Acknowledgements and References.

Short Communications (~500 words) should have the above section headings and a brief summary (~50 words).

Titles These are most important; authors should compose them with great care. They should combine brevity with clarity; the shorter the better, not exceeding 100 letters. Authors should submit their own running title, which must not exceed 50 letters.

References Only papers closely related to the author’s work should be quoted, and these should where possible be original papers rather than reviews. Exhaustive lists should be avoided. Citation of Conference Proceeding or Meeting Abstracts should also be avoided unless there is no other reference. References in the text should be made by giving the author’s surname, with the year of publication in brackets. When the reference is to a specific part of a book, the page number should also be cited. When reference is made to a work by 3 or more authors, the first name followed by et al. should be used. If several papers by the same first author and from the same year are cited, a, b, c, etc. should be added after the year of publication. It is the author’s responsibility to check the accuracy of all references before submitting a manuscript. References should be brought together at the end of the paper in alphabetical order, where titles of papers and all authors’ names should be given in full. Names of journals should be abbreviated as in the Index Medicus, but with full stops after abbreviations (and after authors’ initials), followed by the volume number and the initial and final page numbers, e.g.: McMANUS, M.J., DOMBROSKE, S.E., PIENKOWSKI, M.M. & WILSON, A.B. (1978). Successful transplantation of human beings using an immunodepleted mouse and demonstration of enhanced DNA synthesis by human placental lactogen. Cancer Res., 38, 2243–2248.

References to books and monographs should appear as in the following examples:

Abbreviations and units should follow the standards laid down in Units Symbols and Abbreviations published by the Royal Society of Medicine (third edition, 1977).

Figures In the text Arabic numbers should be used and all illustrations should be specifically referred to in the text, e.g. (Figure 2). All illustrations should be submitted at about 14 times the intended final size and should be numbered as figures whether they are photographs, representational drawings or line diagrams and graphs. Copies of all Figures must accompany each of the 3 submitted copies of the manuscript.

Photographs and photomicrographs should be unmounted glossy prints, should not be retouched, and should be chosen to exclude technical artefacts. Magnification should be indicated by a line representing a defined length included within the photograph. Areas of key interest and/or critical reproduction should be indicated on a flimsy overlay attached to the photograph or on a photocopy. All annotation and lettering should be indicated in the same way, and preferably not included on the original print. Clearly contrasted and focussed prints are essential for adequate reproduction. Three originals of all photographs must be submitted. Photocopies of half-tone illustrations are generally unsuitable for refereeing purposes.

Full colour illustrations may be included within the text, at the discretion of the Editor. However, a charge will be made to the author to cover the extra costs incurred in originating and printing of colour illustrations. Authors will be advised of any such charges, which depend on the size and quantity of colour illustrations, prior to publication.

Line diagrams and graphs should be on separate sheets; they must be drawn with black ink on white paper or represent computer-generated output printed using laser or ink jet printers with appropriate line-smoothing facilties. Lettering on figures should be minimal and must not duplicate the legend. The use of symbols should be consistent within papers, and explanation of symbols should be included in the caption, not on the figure. Symbols should be sufficiently large that they will be clearly discernible following reduction.

Tables These should be as few as possible and should present only essential data. They should be typewritten on separate sheets, have a title or caption, and given Roman numbers.

Proofs Two marked copies of the proofs will be sent to the principal author and should be read carefully for errors. One corrected copy must be returned to the Editor within 3 days. Major alterations to the text cannot be accepted.

Copyright Assignment The principal author must complete and return to the Publisher the Copyright Assignment Form enclosed with the proofs.

Offprints Twenty-five offprints will be supplied free of charge to the principal author. Additional offprints may be ordered on the form accompanying proofs. The charges are necessarily higher if orders are received after the issue has gone to press.

*Editorial correspondence (other than in direct response to a communication from the Clinical Editor) should be addressed to Dr P.R. Twyman, Editor, British Journal of Cancer, MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK.